Hemophilia More Prevalent Than Previously Estimated
By HospiMedica International staff writers Posted on 01 Oct 2019 |
A new study reveals that over 1,125,000 men around the world have inherited hemophilia, three times more than previously estimated.
Researchers at McMaster University (Hamilton, ON, Canada), the World Federation of Hemophilia (WFH; Montréal, Canada), and other institutions conducted a random-effects meta-analysis of registry data from Australia, Canada, France, Italy, New Zealand, and the United Kingdom in order to estimate the prevalence and prevalence at birth of male patients with hemophilia A or B in proportion to total male population, life expectancy disadvantage as related to prevalence at birth, and the expected number of patients worldwide.
The results revealed a prevalence of hemophilia A of 17.1 cases per 100,000 males for all severities of hemophilia, six cases for severe hemophilia A, 3.8 cases for all severities of hemophilia B, and 1.1 cases for severe hemophilia B. Prevalence at birth is 24.6 cases for all severities of hemophilia A, 9.5 cases for severe hemophilia A, five cases for all severities of hemophilia B, and 1.5 cases for severe hemophilia B. The life expectancy disadvantage (in high-income countries) is thus 30% for hemophilia A, 37% for severe hemophilia A, 24% for hemophilia B, and 27% for severe hemophilia B. The study was published on September 10, 2019, in Annals of Internal Medicine.
“The expected number of patients with hemophilia worldwide is 1,125,000, of whom 418,000 should have severe hemophilia,” said lead author Professor Alfonso Iorio, MD, PhD, director of the Hamilton-Niagara hemophilia program at McMaster University. “Knowing how many patients are out there will enable health care systems to estimate the resources needed to treat the disease, and enable drug manufacturers to increase the investment in research to match the demand of a patient population three times larger than we previously thought.”
Hemophilia, which is found almost only in men, is caused by a genetic defect. The most common type is hemophilia A, due to a lack of clotting factor VIII. Hemophilia B, which is less common, is caused by a lack in factor IX. Hemophilia is currently treated with infusions of the missing factors to prevent or stop debilitating bleeds, but treatment is expensive and scarce in many countries. Lack of treatment leads to chronic, disabling joint disease, while bleeding into organs and brain hemorrhages can lead to disability and death.
Related Links:
McMaster University
World Federation of Hemophilia
Researchers at McMaster University (Hamilton, ON, Canada), the World Federation of Hemophilia (WFH; Montréal, Canada), and other institutions conducted a random-effects meta-analysis of registry data from Australia, Canada, France, Italy, New Zealand, and the United Kingdom in order to estimate the prevalence and prevalence at birth of male patients with hemophilia A or B in proportion to total male population, life expectancy disadvantage as related to prevalence at birth, and the expected number of patients worldwide.
The results revealed a prevalence of hemophilia A of 17.1 cases per 100,000 males for all severities of hemophilia, six cases for severe hemophilia A, 3.8 cases for all severities of hemophilia B, and 1.1 cases for severe hemophilia B. Prevalence at birth is 24.6 cases for all severities of hemophilia A, 9.5 cases for severe hemophilia A, five cases for all severities of hemophilia B, and 1.5 cases for severe hemophilia B. The life expectancy disadvantage (in high-income countries) is thus 30% for hemophilia A, 37% for severe hemophilia A, 24% for hemophilia B, and 27% for severe hemophilia B. The study was published on September 10, 2019, in Annals of Internal Medicine.
“The expected number of patients with hemophilia worldwide is 1,125,000, of whom 418,000 should have severe hemophilia,” said lead author Professor Alfonso Iorio, MD, PhD, director of the Hamilton-Niagara hemophilia program at McMaster University. “Knowing how many patients are out there will enable health care systems to estimate the resources needed to treat the disease, and enable drug manufacturers to increase the investment in research to match the demand of a patient population three times larger than we previously thought.”
Hemophilia, which is found almost only in men, is caused by a genetic defect. The most common type is hemophilia A, due to a lack of clotting factor VIII. Hemophilia B, which is less common, is caused by a lack in factor IX. Hemophilia is currently treated with infusions of the missing factors to prevent or stop debilitating bleeds, but treatment is expensive and scarce in many countries. Lack of treatment leads to chronic, disabling joint disease, while bleeding into organs and brain hemorrhages can lead to disability and death.
Related Links:
McMaster University
World Federation of Hemophilia
Latest Critical Care News
- AI Doubles Medical Professionals’ Accuracy in Reading EEG Charts of ICU Patients
- Flexible Device Enables Sweat Gland Stimulation and Simultaneous Biosensing
- WHO Publishes First Global Guidelines to Reduce Bloodstream Infections from Catheter Use
- Innovative Material Paves Way for Next-Generation Wearable Devices
- Wireless Electronic Suture Enables Postoperative Long-Term Monitoring Of Soft Tissue
- Transcatheter Valve Replacement Outcomes Similar To Surgery, Finds Study
- Revascularization Improves Life Quality in Chronic Limb-Threatening Ischemia, Finds Study
- Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients
- Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot
- One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes
- AI Can Prioritize Emergency Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD